Article

Stimulant therapy and seizure risk in children with ADHD

Northwestern University, Evanston, Illinois, United States
Pediatric Neurology (Impact Factor: 1.5). 03/2001; 24(2):99-102. DOI: 10.1016/S0887-8994(00)00240-X
Source: PubMed

ABSTRACT Stimulants are an effective treatment frequently prescribed for attention-deficit-hyperactivity disorder (ADHD), but they commonly are believed to lower the threshold for seizures. Although several studies have revealed that stimulants do not exacerbate well-controlled epilepsy, there is a paucity of data about seizure risk in nonepileptic children treated with stimulants. Two hundred thirty-four children (179 males, 9.1 +/- 3.6 years of age; 55 females, 9.6 +/- 3.9 years of age) with uncomplicated ADHD received electroencephalograms (EEGs) performed in our institution. Thirty-six patients (15.4%) demonstrated epileptiform abnormalities, and 198 (84.6%) demonstrated normal or nonepileptiform EEGs. Rolandic spikes accounted for 40% of the abnormal EEGs and 60% of those with focal abnormalities. Stimulant therapy was elected by 205 of 234 patients (87.6%). Seizures occurred only in the treated group, in one of 175 patients with a normal EEG (incidence 0.6%, 95% confidence intervals 0%-1.7%) and three of 30 treated patients with epileptiform EEGs (incidence 10%, 95% confidence interval 0%-20.7%). Seizures occurred in two of 12 children (16.7%) with rolandic spikes. These data suggest that a normal EEG can be used to assign children with ADHD to a category of minimal risk for seizure. In contrast, an epileptiform EEG in neurologically normal children with ADHD predicts considerable risk for the eventual occurrence of seizure. The risk, however, is not necessarily attributable to stimulant use.

0 Followers
 · 
88 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study investigated whether interictal epileptiform discharges (IED) on a baseline routine EEG in children with ADHD was associated with the occurrence of epileptic seizures (Sz) or influenced the use of methylphenidate (MPH) during two years follow-up.
    Seizure 01/2015; 25. DOI:10.1016/j.seizure.2015.01.002 · 2.06 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To retrospectively examine response to stimulant treatment in patients with epilepsy and ADHD symptoms as predicted by seizure freedom for six months, use of methylphenidate (MPH) versus amphetamine (AMP) preparations, cognitive level, and medical records were searched for patients under the age of 18 with epilepsy and ADHD symptoms treated with MPH or AMP (n=36, age=10.4±3.5; male=67%). "Responders" had a CGI-improvement score of ≤2 and did not stop medication because of adverse effects. "Worsened" patients discontinued medication because of agitation/emotional lability. Seizure freedom did not predict treatment response. Lower cognitive level was associated with increased rate of worsening (p=0.048). No patients who were seizure-free at the start of the medication trial experienced an increase in seizures. Of the patients having seizures at the start of trial, one patient on MPH and two patients on AMP had increased seizures during the trial. Seizures returned to baseline frequency or less after stimulant discontinuation or anticonvulsant adjustment. Methylphenidate was associated with a higher response rate, with 12 of 19 given MPH (0.62±0.28mg/kg/day) compared with 4 of 17 given AMP (0.37±0.26mg/kg/day) responding (p=0.03). Methylphenidate treatment and higher cognitive level were associated with improved treatment outcome, while seizure freedom had no clear effect. Confidence in these findings is limited by the study's small, open-label, and uncontrolled design.
    Epilepsy & Behavior 06/2014; 36C:102-107. DOI:10.1016/j.yebeh.2014.04.026 · 2.06 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: To investigate in the literature elements that explain the association between the attention deficit hyperactivity disorder (ADHD) and epilepsy and to provide clinical guidelines for the management of patients that share these disorders. METHODS:Review of literature of the last 10 years in MedLine and Lilacs databases. The keywords used were "attention deficit hyperactivity disorder", "ADHD" and "epilepsy. RESULTS: Symptoms of ADHD are more frequent in idiopathic epilepsies. Several factors may contribute to this comorbidity: 1) common genetic environment; 2) participation of neurotransmitters norepinephrine and dopamine in ADHD and in neuronal excitability modulation; 3) the underlying brain structural abnormalities found in epileptic patients with ADHD; 4)the chronic effects of seizures and of the epileptiform interictal EEG discharges in attention; 5) the cognitive side effects of antiepileptic drugs. CONCLUSIONS: Recents evidences suggest that seizures and ADHD may have common neurobiological bases. Researches that investigate dysfunctions in cerebral cathecholamines pathways and the role of the interictal epileptiform discharges in the generation of the sintoms are essencial to understand these mechanisms. Treatment for ADHD with stimulant drugs are safe and effective in most epileptic patients.
    Jornal brasileiro de psiquiatria 12/2009; 59(2):146-155. DOI:10.1590/S0047-20852010000200011